Sort   by:  
 Page size 
TranscriptomicsIGR_Itzykson_CMML
Genomic studies in chronic myeloid malignancies, including myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS) and MPN/MDS, have identified common mutations in genes encoding signaling, epigenetic, transcription and splicing factors. Analysis of 18 of these genes in a cohort of 224 c...
ORGANISM(S): Homo sapiens 
2013-01-17 | E-MTAB-1044 | biostudies-arrayexpress
TranscriptomicsABT-737 treatment induces regulation and activation of pathways implicated in cell survival, proliferation and stem cells in treated AML mice survival, proliferation and stem cells in treated AML mice
Myelodysplastic syndrome (MDS) transforms into an acute myelogenous leukemia (AML) with associated increased bone marrow blast infiltration. Using a transgenic mouse model, MRP8[NRASD12/hBCL-2], in which the NRAS:BCL-2 complex at the mitochondria induces MDS progressing to AML with dysplastic featur...
ORGANISM(S): Mus musculus 
2013-11-06 | E-GEOD-48601 | biostudies-arrayexpress
UnknownOutcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study.
Not available
S-EPMC8318880 | biostudies-literature
UnknownGuadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial.
Not available
S-EPMC11103175 | biostudies-literature
UnknownReducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial).
Not available
S-EPMC6278967 | biostudies-literature
UnknownGuadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study.
Not available
S-EPMC10471926 | biostudies-literature
UnknownPhase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome.
Not available
S-EPMC4053545 | biostudies-literature
UnknownRuxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study.
Not available
S-EPMC9412002 | biostudies-literature
UnknownOlutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML.
Not available
S-EPMC10362540 | biostudies-literature
UnknownDyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes.
Not available
S-EPMC6395339 | biostudies-literature
Sort   by:  
 Page size